Skip to main content


Grants & Investigator Sponsored Research (ISR) Program

Enterra Medical is dedicated to supporting educational and scientific advancements through the support of the grants or ISR support program. Each submission is evaluated by the grants or ISR committee for scientific merit and alignment with Enterra Medical’s strategic initiatives. For consideration, please submit your request below.

MKT-D-0006, Rev M


Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.


Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?